PRMT3 and breast carcinoma: While studies of PRMT3 focus more on the control of apoptosis and tumor progression in breast cancer [110,111], its involvement in PDAC has been mainly associated with chemo-resistance [112], likely due to PRMT3-mediated metabolic reprograming of PDAC cells [109].